Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 18/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 18/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.65 |
| ▸ | DRD2 | P14416 | 1/20 | 0.64 |
| ▸ | DRD3 | P35462 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8072372 | 0.80 | ADORA2A (0.73) | ADORA2AADORA1ADORA2BADORA3HRH3 | |
| SCHEMBL1830502 | 0.77 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3HRH3 | |
| SCHEMBL11767865 | 0.75 | MAPT (0.89) | ADORA2AADORA1MAPTCHRNA7KMT2A | |
| SCHEMBL1791615 | 0.74 | MAPT (0.88) | ADORA2AADORA1MAPTCHRNA7KMT2A | |
| SCHEMBL11852663 | 0.74 | MAPT (0.94) | ADORA2AADORA1MAPTCHRNA7KMT2A | |
| SCHEMBL5604767 | 0.74 | MAPT (0.94) | ADORA2AADORA1MAPTCHRNA7KMT2A | |
| SCHEMBL8037347 | 0.74 | ADORA2A (0.71) | ADORA2AADORA1 | |
| Hydrochloric Acid SCHEMBL11835509 | 0.73 | MAPT (0.91) | ADORA2AADORA1MAPTCHRNA7KMT2A | |
| Hydrochloric Acid SCHEMBL11836743 | 0.73 | MAPT (0.91) | ADORA2AADORA1MAPTCHRNA7KMT2A | |
| SCHEMBL8073095 | 0.73 | ADORA2A (0.69) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220053-B1 | ARYLINDENOPYRIMIDINES AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-11 | — | — | EP | disclosed |
| US-20090111804-A1 | ARYLINDENOPYRIMIDINES AND THEIR USE AS ADENOSINE A2a | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111804-A1 | ARYLINDENOPYRIMIDINES AND THEIR USE AS ADENOSINE A2a | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| WO-2009055548-A1 | ARYLINDENOPYRIMIDINES AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111804-A1 | ARYLINDENOPYRIMIDINES AND THEIR USE AS ADENOSINE A2a | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885ADORA1 4/4885ADORA2B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.